Sanofi Finalizes Acquisition of Vigil Neuroscience

Sanofi has completed the acquisition of Vigil Neuroscience, Inc., enhancing its neurology pipeline. The acquisition brings VG-3927, a TREM2 agonist, to Sanofi's portfolio, with plans for a phase 2 clinical study in Alzheimer's patients. This move bolsters Sanofi’s research in neurodegenerative diseases.

In June 2024, Sanofi invested $40 million in Vigil, securing negotiation rights for VG-3927. Under the acquisition terms, Sanofi bought all Vigil shares for $8 each, valuing the deal at approximately $470 million. Vigil shareholders received a contingent value right for an additional $2 per share, payable upon VG-3927's commercial launch.

Sanofi did not acquire Vigil's second clinical program, VGL101. The acquisition does not alter Sanofi's 2025 financial projections.